Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition

NCT01577914 | Completed Phase 1 DMC

• 1 other identifier: Ipca/ARL/203
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult, human subjects.

Conditions

Fasting State

Outcome Measures

Primary Outcomes (1)

• Bioequivalence is based on Cmax and AUC parameters.Sampling Hours: Pre-dose and at 00.50, 00.75, 01.00, 01.25, 01.50, 01.75, 02.00, 02.50, 03.00, 04.00, 05.00, 06.00, 08.00, 09.00, 10.00, 12.00, 16.00, 20.00, 24.00, 36.00 and 48.00 hours post-dose.

  Bioequivalence was concluded if: The 90% confidence interval of geometric mean ratio of Cmax, AUC0-t and AUC0-inf between test and reference product fall within the range of 80.00 % to 125.00 % for Carvedilol.

  5 months

Study Arms (2)

Carvedilol Tablets USP 12.5 mg

EXPERIMENTAL

Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India

Drug: Carvedilol Tablets USP 12.5 mg

Coreg®

ACTIVE COMPARATOR

Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline

Drug: Carvedilol

Interventions

Carvedilol Tablets USP 12.5 mg DRUG

12.5mg tablet once a day

Also known as: Test Product

Carvedilol Tablets USP 12.5 mg

Carvedilol DRUG

12.5mg tablet once a day

Also known as: Coreg®

Coreg®

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male and female human subjects, age in the range of 18 - 45 years.
• Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart.
• Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and oral temperature).
• Subjects with clinically acceptable findings as determined by haemogram, biochemistry, serology (HIV, Hepatitis B and Hepatitis C), urinalysis, 12 lead ECG and chest X-ray (chest X-ray if required).
• Willingness to follow the protocol requirements as evidenced by written informed consent.
• Confirming and agreeing to, not using any prescription and over the counter medications including vitamins and minerals for 14 days prior to study and during the course of the study.
• No history of drug abuse in the past one year.
• Non-smokers and non-alcoholics.
• For female subject is child bearing potential practicing acceptable method of birth control for the duration of the study as judged by Investigator such as Condom, Foams, Jellies,Diaphragm, Intrauterine device and Abstinence.
• \- is surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject).

You may not qualify if:

• Known history of hypersensitivity to Carvedilol, 4-hydroxyphenyl-carvedilol or related drugs.
• Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day.
• Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
• History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric diseases and bleeding tendency.
• Participation in a clinical drug study or bioequivalence study within 90 days prior to present study.
• History of malignancy or other serious diseases.
• Refusal to abstain from food for at least ten (10) hours prior to study drug administration and for at least four (04) hours post-dose, in each study period.
• Any contraindication to blood sampling or difficulty in accessibility of veins.
• Refusal to abstain from fluid for at least 01.00 hour prior to study drug administration and for at least 01.00 additional hour post-dose, in each study period except about 240 mL of water given during administration of study drug.
• Refusal to avoid the use of xanthine-containing food or beverages (chocolates,tea, coffee or cola drinks) or fruit juice/grapefruit juice and any alcoholic products for 48.00 hours prior to dosing until the last blood sample collection of last study period.
• Blood donation within 90 days prior to the commencement of the study.
• Subjects with positive HIV tests or Hepatitis-B or Hepatitis-C tests.
• Found positive in breath alcohol test done before check-in for each study period.
• Found positive in urine test for drugs of abuse done before check-in for each study period.
• Refusal to abstain from consumption of tobacco products 24 hours prior to dosing until the last blood sample collection of last study period.

Sponsors & Collaborators

• IPCA Laboratories Ltd.: lead

Study Sites (1)

Accutest Research Lab (I) Pvt. Ltd.

Ahmedabad, Gujarat, India

Location

MeSH Terms

Interventions

Carvedilol

Intervention Hierarchy (Ancestors)

Propanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Propanols; Amines; Carbazoles; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 3-Ring

Study Officials

• Dr. Tarang Shah, M.D.

  Accutest Research Lab (I) Pvt. Ltd.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 12, 2012
• First Posted: April 16, 2012
• Study Start: July 1, 2011
• Primary Completion: November 1, 2011
• Study Completion: November 1, 2011
• Last Updated: July 9, 2012

Record last verified: 2012-07

Locations

IN (1)